Search Results

President Donald Trump loves a deal, but Most Favored Nation drug pricing isn’t a good one for anyone.

Gilgamesh Pharmaceuticals today announced that it has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, its novel, cardiac-safe ibogaine analog for the treatment of substance use disorders.

Cessation Therapeutics, Inc. today announced that it has been awarded an additional grant from the National Institute on Drug Abuse (NIDA, a division of the National Institutes of Health).

As Trump has pressured drugmakers to lower the cost of medicines in the U.S., the pharma industry has coalesced behind a message of rebalancing what nations pay to better reflect the innovation and value of drugmaking.

STALICLA SA, a clinical stage biotech advancing the first precision neurobiology platform (DEPI) for patients with neurodevelopmental and neuropsychiatric disorders, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the US National Institute on Drug Abuse (NIDA), part of the US National Institutes of Health (NIH).

Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other pharmaceutical companies to lower drug prices or face consequences.

MAPS Public Benefit Corporation (“MAPS PBC”) announced that the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health, has agreed to provide data to supplement the company’s new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for MDMA-assisted therapy as a treatment for post-traumatic stress disorder (“PTSD”).